Current Clinical Trials

An open-Label Study Of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

Phase 1 Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or In Combinations with systemic Anti-Cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

Phase I, dose escalation study of ALX148 in patients with advanced solid tumors or lymphoma examining safety, pharmacokinetics and tolerability. NOW IN COMBINATION PHASE II WITH PEMBROLIZUMAB, RITUXIMAB AND TRASTUZUMAB

A Phase I Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID 200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies

Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

A Non-interventional Biomarker Study on the Molecular Evaluation (KRAS G12C) of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer

(NSCLC)

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Principle Investigator: Dr. Chen

A multicenter, low-interventional study enrolling metastatic or recurrent Non-Small Cell Lung Cancer or extensive-disease Small-Cell Lung Cancer patients, who are planning to initiate standard-of-care systemic anti-cancer treatment, for the purpose of collecting blood and tissue samples to be used for genomic profiling (results of tests will be provided to treating physician).

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Principle Investigator: Dr. Chen

A Phase 1/2 First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Primary Investigator: Dr. O’Rourke

Expanded access to mepolizumab for patients with hypereosinophilic syndrome

Principal Investigator: Dr. Gribbin

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

An open-Label Study Of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (ARRAY-818-201)

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from twelve primary cancer diagnoses: breast, lung, colorectal, prostate, bladder, uterine, kidney and renal pelvis, pancreatic, liver, stomach, ovarian, esophageal

Principle Investigator: Dr. Chandana